TRI-MED's mission is to develop 'Health Products For The Future Today'. Working in partnership with the health sector and the community as a whole is what we at TRI-MED strive to achieve.

Our organisation is committed to research, development, manufacture and distribution of diagnostic devices and novel anti-infective therapeutics specifically related to the ulcer causing bacterium Helicobacter pylori and other gastrointestinal infective agents.

TRI-MED is continuously developing novel products, and improving its current diverse product range of quality diagnostics devices to world-class status. TRI-MED is a biotechnology organisation for the future, today.

Our strategic alliance with Ballard Medical Products (a wholly owned subsidiary of Kimberly Clark Corporation) and Romark Pharmaceuticals enhances our research and development base, ensuring that TRI-MED becomes one of the foremost contenders for the entire health sector in Australia and globally.